CA2394880A1 - Activation and inhibition of the immune system - Google Patents

Activation and inhibition of the immune system Download PDF

Info

Publication number
CA2394880A1
CA2394880A1 CA002394880A CA2394880A CA2394880A1 CA 2394880 A1 CA2394880 A1 CA 2394880A1 CA 002394880 A CA002394880 A CA 002394880A CA 2394880 A CA2394880 A CA 2394880A CA 2394880 A1 CA2394880 A1 CA 2394880A1
Authority
CA
Canada
Prior art keywords
inhibitor
cells
inducer
mammal
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002394880A
Other languages
English (en)
French (fr)
Inventor
Brian Foxwell
Marc Feldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Kennedy Trust for Rheumatology Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2394880A1 publication Critical patent/CA2394880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002394880A 1999-12-24 2000-12-22 Activation and inhibition of the immune system Abandoned CA2394880A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930616.9A GB9930616D0 (en) 1999-12-24 1999-12-24 Activation and inhibition of the immune system
GB9930616.9 1999-12-24
PCT/GB2000/004925 WO2001047543A2 (en) 1999-12-24 2000-12-22 Activation and inhibition of the immune system

Publications (1)

Publication Number Publication Date
CA2394880A1 true CA2394880A1 (en) 2001-07-05

Family

ID=10867023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002394880A Abandoned CA2394880A1 (en) 1999-12-24 2000-12-22 Activation and inhibition of the immune system

Country Status (12)

Country Link
US (2) US7915009B2 (cg-RX-API-DMAC7.html)
EP (2) EP1852123A3 (cg-RX-API-DMAC7.html)
JP (1) JP2003518507A (cg-RX-API-DMAC7.html)
CN (2) CN1254272C (cg-RX-API-DMAC7.html)
AT (1) ATE390929T1 (cg-RX-API-DMAC7.html)
AU (1) AU781496B2 (cg-RX-API-DMAC7.html)
CA (1) CA2394880A1 (cg-RX-API-DMAC7.html)
DE (1) DE60038503T2 (cg-RX-API-DMAC7.html)
ES (1) ES2302707T3 (cg-RX-API-DMAC7.html)
GB (1) GB9930616D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ519438A (cg-RX-API-DMAC7.html)
WO (1) WO2001047543A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1345617A2 (en) * 2000-12-22 2003-09-24 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
JP2003055202A (ja) * 2001-08-15 2003-02-26 Hiroyuki Hanai 炎症性腸疾患の予防・治療剤
CN1306964C (zh) * 2002-05-29 2007-03-28 安琪士摩奇株式会社 治疗和预防炎症性疾病的诱饵组合物
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
WO2004027063A1 (en) * 2002-09-19 2004-04-01 Institut National De La Sante Et De La Recherche Medicale-Inserm Use of sirnas for gene silencing in antigen presenting cells
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
US20050147608A1 (en) * 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
KR20080052549A (ko) * 2005-06-23 2008-06-11 베이롤 칼리지 오브 메드신 네거티브 면역 조절인자의 조절 및 면역요법을 위한 적용
CA2623153A1 (en) * 2005-09-20 2007-03-29 London Health Sciences Centre Research Inc. The use of sirnas in organ storage/reperfusion solutions
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
CA2702340C (en) * 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP6313203B2 (ja) * 2011-07-18 2018-04-18 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションUniversity Of Kentucky Research Foundation Alu−rna誘導変性からの細胞の保護及び細胞保護用阻害剤
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
EP3043641B1 (en) * 2013-09-12 2019-09-11 Icahn School of Medicine at Mount Sinai Methods of making transgenic animals with t cell receptors that are specific to a flourescent protein
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US20150342961A1 (en) * 2014-06-03 2015-12-03 Hai-Hui Xue Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
CR20210587A (es) 2019-05-31 2022-02-11 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
EP0500785B1 (en) 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
US5597898A (en) 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
WO1997001340A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal mast cell stabilizers
EP0779361A3 (en) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FI990180A7 (fi) * 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
CA2263835C (en) * 1996-08-26 2012-02-21 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6924308B1 (en) 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US5952483A (en) 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
EP0897009A3 (en) 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子NF−κB活性化阻害剤
GB9719238D0 (en) 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5965421A (en) 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
WO1999042137A2 (en) 1998-02-19 1999-08-26 Peter Bromley Stress promoter control of therapeutic genes in gene therapy: compositions and methods
ATE309352T1 (de) * 1998-05-06 2005-11-15 Vlaams Interuniv Inst Biotech Inhibitoren der nf-kb aktivierung
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP1345617A2 (en) 2000-12-22 2003-09-24 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods

Also Published As

Publication number Publication date
CN1254272C (zh) 2006-05-03
US7915009B2 (en) 2011-03-29
EP1852123A3 (en) 2008-09-10
US20080124322A1 (en) 2008-05-29
JP2003518507A (ja) 2003-06-10
WO2001047543A3 (en) 2002-01-17
CN100563707C (zh) 2009-12-02
CN1817367A (zh) 2006-08-16
EP1244466B1 (en) 2008-04-02
DE60038503D1 (de) 2008-05-15
US20030153518A1 (en) 2003-08-14
CN1434718A (zh) 2003-08-06
ATE390929T1 (de) 2008-04-15
AU2206201A (en) 2001-07-09
WO2001047543A2 (en) 2001-07-05
EP1244466A2 (en) 2002-10-02
DE60038503T2 (de) 2009-04-30
EP1852123A2 (en) 2007-11-07
NZ519438A (en) 2004-03-26
ES2302707T3 (es) 2008-08-01
AU781496B2 (en) 2005-05-26
GB9930616D0 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
US7915009B2 (en) Activation and inhibition of the immune system
EP1658097B1 (en) Nucleotide and cellular vaccine composition
US6652860B1 (en) Peptide, apoEp 1.B, compositions and uses thereof
US7517948B2 (en) Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
EP0964697B1 (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
US7651857B2 (en) Methods for enhancing antigen presentation
WO2004053095A2 (en) In situ maturation of dendritic cells
US20040241152A1 (en) Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab
WO2006072946A2 (en) Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
US20030072743A1 (en) Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
EP2393505B1 (en) Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm)
AU2002314374A1 (en) Methods for inducing an immune response with an elevated TH1/TH2 ratio by intracellular induction of NFKAPPAB
Gallucci Novel activators of dendritic cells as fundamental tools in immunotherapy
WO2007025554A1 (en) Method for the generation of antigen-specific t-cells and uses thereof
Lutzky et al. Dendritic cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued